NX-5948, a Selective Degrader of BTK With Activity in Preclinical Models of Hematologic and Brain Malignancies

Daniel W. Robbins,1 Mark Noviski,1 Ryan Roumoute,1 May Yan,3 Nivetha Brathaban,3 Timothy Ingallina1,3 Dale Karr,1 Aileen Kelly,1 Zef Konst,1 Jun Ma,1 Austin Tenn-McClellan,1 Jenny McKinnell,1 Luz Perez,1 Cristina Guiducci1,2 Gwenn Hansen1,3 and Arthur T. Sands1

1Nurix Therapeutics, San Francisco, CA, USA

RESULTS (continued)

Figure 3. NX-5948 Decreases Viability of TMD8 Cells With Wildtype and C481S-Mutated BTK

Figure 4. NX-5948 Catalyzes Selective BTK Degradation

Figure 5. NX-5948 Increases Viability of TMD8 Cells Compared to DMSO

Figure 6. Daily Oral Dosing of NX-5948 Leads to Regression of Tumors in a Mouse Model of Brutonist-Resistant DLBCL

Figure 7. NX-5948 Promotes BTK Degradation in Brain-Resistant TMD8 Tumor Cells and Microglia

Figure 8. NX-5948 Reduces Tumor Burden and Prolongs Survival in Mice With Intracranial TMD8 Tumors

REFERENCES


ACKNOWLEDGMENTS

1. This work was supported by grants from the National Institutes of Health (NIH) (T32 GM08544, R01 CA270457, and R01 NS113290), the Leukemia & Lymphoma Society, the Multiple Myeloma Research Foundation, the National Multiple Sclerosis Society, and the NIH Roadmap for Medical Research (U54HG007968). NX-5948 is a selective inhibitor of BTK with activity in preclinical models of hematologic malignancies and brain tumors.

DISCLOSURES

1. All authors have declared no conflicts of interest.

CONCLUSIONS

1. NX-5948 is a selective degrader of BTK with potent antitumor activity in a mouse model of druzilest-resistant diffuse large B cell lymphomas.

2. NX-5948 crosses the blood-brain barrier and mediates BTK degradation in brain-resident tumor cells and microglia.

3. NX-5948 reduces tumor burden and extends survival in a mouse model of primary central nervous system lymphoma.

4. These findings support clinical development of NX-5948 for the treatment of B cell malignancies, including primary central nervous system lymphoma.

Presented at the 63rd American Society of Hematology (ASH) Annual Meeting, December 11-14, 2021, Atlanta, GA